Kirk G. Nielsen - 09 Feb 2026 Form 4 Insider Report for SpyGlass Pharma, Inc. (SGP)

Role: Director
Signature: /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen
Issuer symbol: SGP
Transactions as of: 09 Feb 2026
Net transactions value: +$2,640,000
Form type: 4
Filing time: 10 Feb 2026, 18:09:42 UTC
Previous filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nielsen Kirk G.	Director	C/O SPYGLASS PHARMA, INC. 27061 ALISO, CREEK RD., SUITE 100, ALISO VIEJO	/s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen	10 Feb 2026	0001523522

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGP	Common Stock	Conversion of derivative security		+1,690,230			1,690,230	09 Feb 2026	See footnote	F1, F2
transaction	SGP	Common Stock	Conversion of derivative security		+548,067	+32%		2,238,297	09 Feb 2026	See Footnote	F1, F2
transaction	SGP	Common Stock	Conversion of derivative security		+548,067	+24%		2,786,364	09 Feb 2026	See Footnote	F1, F2
transaction	SGP	Common Stock	Conversion of derivative security		+359,255	+13%		3,145,619	09 Feb 2026	See Footnote	F1, F2
transaction	SGP	Common Stock	Purchase	$2,640,000	+165,000	+5.2%	$16.00	3,310,619	09 Feb 2026	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	SGP	Series B Preferred Stock	Conversion of derivative security	-9,689,922	-100%	09 Feb 2026	Common Stock	1,690,230	See Footnote	F1, F2
transaction	SGP	Series C-1 Preferred Stock	Conversion of derivative security	-3,142,015	-100%	09 Feb 2026	Common Stock	548,067	See Footnote	F1, F2
transaction	SGP	Series C-2 Preferred Stock	Conversion of derivative security	-3,142,015	-100%	09 Feb 2026	Common Stock	548,067	See Footnote	F1, F2
transaction	SGP	Series D Preferred Stock	Conversion of derivative security	-2,059,573	-100%	09 Feb 2026	Common Stock	359,255	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2	These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Content

Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.